Drug updated on 9/4/2024
Dosage Form | Tablet (oral; 185 mg) |
Drug Class | Penicillin class antibacterial |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of female patients 18 years of age and older with uncomplicated urinary tract infections (uUTI) caused by susceptible isolates of Escherichia coli, Proteus mirabilis and Staphylococcus saprophyticus.
Latest News
Summary
- Pivya (Pivmecillinam) is indicated for the treatment of female patients 18 years of age and older with uncomplicated urinary tract infections (uUTI) caused by susceptible isolates of Escherichia coli, Proteus mirabilis, and Staphylococcus saprophyticus.
- This summary is based on the review of one randomized controlled trial(s). [1]
- Symptomatic Resolution by Day 4: Pivmecillinam achieved symptomatic resolution in 73.6% of patients by day 4, compared to 38.7% with ibuprofen, with a risk difference of 35% favoring pivmecillinam (90% CI: 27% to 43%).
- Secondary Outcomes - Antibiotic Treatment and Pyelonephritis: Pivmecillinam showed more favorable outcomes in reducing the need for secondary antibiotic treatment. All 7 cases of pyelonephritis occurred in the ibuprofen group.
- There is no safety information available in the reviewed studies.
- The study focuses on non-pregnant women aged 18-60 years with symptoms of uncomplicated UTI in Norway, Sweden, and Denmark, noting that extensive exclusion criteria and the lack of symptom registration for non-participants may limit the generalizability of the findings.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Pivya (pivmecillinam) Prescribing Information. | 2024 | Utility therapeutics Ltd., UK |
Randomized Controlled Trials
Document Title | Sex Distribution | Year | Source |
---|---|---|---|
Ibuprofen versus pivmecillinam for uncomplicated urinary tract infection in women-A double-blind, randomized non-inferiority trial. | 383Subjects F: 100% M: 0% | 2018 | PLoS Medicine |
Sex Distribution:
F:100%
M:0%
383Subjects
Year:
2018
Source:PLoS Medicine
Clinical Practice Guidelines
Document Title | Year | Source |
---|---|---|
A global perspective on improving patient care in uncomplicated urinary tract infection: expert consensus and practical guidance. | 2022 | Journal of Global Antimicrobial Resistance |
Antibiotic prescribing patterns and guideline concordance for uncomplicated urinary tract infections among adult women in the US Military Health System. | 2022 | JAMA Network Open |